A Randomized Controlled Phase II Study of Nab-Paclitaxel vs. Paclitaxel plus Cisplatin in Concomitant Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer

被引：0
|
作者：
Yang, W., Sr. [1 ]
机构：
[1] Guizhou Canc Hosp, Guiyang, Guizhou, Peoples R China
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2023年 / 117卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2171
引用
收藏
页码：E78 / E78
页数：1
相关论文
共 50 条
  • [31] A randomized prospective study comparing concomitant chemoradiotherapy using paclitaxel-carboplatin with concomitant chemoradiotherapy using etoposide-cisplatin in inoperable or nonresectable locally advanced non-small cell lung cancer
    Srinivasa, G. Y.
    Gupta, Manish
    Seam, Rajeev K.
    Rana, Sakshi
    Verma, Shalini
    Gupta, Manoj
    CLINICAL CANCER INVESTIGATION JOURNAL, 2020, 9 (02): : 27 - 33
  • [32] A single-arm phase II study of nab-paclitaxel for patients with chemorefractory non-small cell lung cancer
    Hisashi Tanaka
    Kageaki Taima
    Takeshi Morimoto
    Yoshihito Tanaka
    Masamichi Itoga
    Kunihiko Nakamura
    Akihito Hayashi
    Mika Kumagai
    Hideo Yasugahira
    Megumi Mikuniya
    Koichi Okudera
    Shingo Takanashi
    Sadatomo Tasaka
    BMC Cancer, 17
  • [33] Single-Arm Phase II Study of Nab-Paclitaxel for Patients with Chemorefractory Non-Small Cell Lung Cancer
    Tanaka, Hisashi
    Taima, Kageaki
    Morimoto, Takeshi
    Tanaka, Yoshihito
    Itoga, Masamichi
    Nakamura, Kunihiko
    Hayashi, Akihito
    Kumagai, Mika
    Yasugahira, Hideo
    Mikuniya, Megumi
    Okudera, Koichi
    Takanashi, Shingo
    Tasaka, Sadatomo
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S922 - S922
  • [34] A single-arm phase II study of nab-paclitaxel for patients with chemorefractory non-small cell lung cancer
    Tanaka, Hisashi
    Taima, Kageaki
    Morimoto, Takeshi
    Tanaka, Yoshihito
    Itoga, Masamichi
    Nakamura, Kunihiko
    Hayashi, Akihito
    Kumagai, Mika
    Yasugahira, Hideo
    Mikuniya, Megumi
    Okudera, Koichi
    Takanashi, Shingo
    Tasaka, Sadatomo
    BMC CANCER, 2017, 17
  • [35] Clinical outcomes of nab-paclitaxel for advanced or relapsed non-small cell lung cancer patients
    Manabe, Saki
    Murakami, Shuji
    Kondo, Tetsuro
    Saito, Haruhiro
    Yamada, Kouzo
    ANNALS OF ONCOLOGY, 2015, 26 : 124 - 124
  • [36] Phase I study of weekly nab-paclitaxel plus carboplatin and concurrent thoracic radiotherapy in elderly patients with unresectable locally advanced non-small cell lung cancer
    Shota Omori
    Hideyuki Harada
    Keita Mori
    Yasushi Hisamatsu
    Yuko Tsuboguchi
    Hiroshige Yoshioka
    Ryotaro Morinaga
    Haruko Daga
    Takayasu Kurata
    Toshiaki Takahashi
    Investigational New Drugs, 2022, 40 : 106 - 114
  • [37] Phase II study of paclitaxel and cisplatin in patients with non-small cell lung cancer
    vonPawel, J
    Wagner, H
    Niederle, N
    Heider, A
    Koschel, G
    Hecker, D
    Hanske, M
    SEMINARS IN ONCOLOGY, 1996, 23 (06) : 47 - 50
  • [38] Phase I study of weekly nab-paclitaxel plus carboplatin and concurrent thoracic radiotherapy in elderly patients with unresectable locally advanced non-small cell lung cancer
    Omori, Shota
    Harada, Hideyuki
    Mori, Keita
    Hisamatsu, Yasushi
    Tsuboguchi, Yuko
    Yoshioka, Hiroshige
    Morinaga, Ryotaro
    Daga, Haruko
    Kurata, Takayasu
    Takahashi, Toshiaki
    INVESTIGATIONAL NEW DRUGS, 2022, 40 (01) : 106 - 114
  • [39] Nab-Paclitaxel in combination with Cisplatin Versus Docetaxel Plus Cisplatin as First-Line Therapy in Non-small Cell Lung Cancer
    Chen, Yi
    Li, Jinyu
    Chen, Shixue
    Zhang, Yibao
    Hu, Yi
    Zhang, Guoqing
    Yan, Xiang
    Jiao, Shunchang
    SCIENTIFIC REPORTS, 2017, 7
  • [40] Phase II study of nab-paclitaxel plus carboplatin for patients with non-small-cell lung cancer and interstitial lung disease
    Kenmotsu, Hirotsugu
    Yoh, Kiyotaka
    Mori, Keita
    Ono, Akira
    Baba, Tomohisa
    Fujiwara, Yutaka
    Yamaguchi, Ou
    Ko, Ryo
    Okamoto, Hiroaki
    Yamamoto, Nobuyuki
    Ninomiya, Takashi
    Ogura, Takashi
    Kato, Terufumi
    CANCER SCIENCE, 2019, 110 (12) : 3738 - 3745
12345